FDA OK's Odomzo from Novartis for common skin cancer type

July 24, 2015 9:20 PM

32 0

A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval.

Odomzo (pronounced ah-DOMM'-zoh) was approved for patients whose cancer hasn't spread to other body parts, but recurred after surgery or radiation therapy or can't be cured by those treatments.

Also read: FDA staff flags concerns about Allergan, Serenity Pharma urinary drug

Read more

To category page